Diagnosis of sepsis or SIRS using biomarker profiles

• US 20080138832A1
• Filed: 09/25/2007
• Published: 06/12/2008
• Est. Priority Date: 11/12/2002
• Status: Abandoned Application

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Gentle, Thomas M., Garrett, James, Tice, Gregory, Shi, Song, Moore, Richard L., Nadeau, James G., Rosenstein, Robert W., Goldenbaum, Paul E., Copertino, Donald, Ivey, Richard M., Towns, Michael L., Bachur, Nicholas
• Application Number:
  US11/904,282
• Publication Number:
  US 20080138832A1
• Time in Patent Office: Days
• US Class Current: 435/7.1
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2800/26 Infectious diseases, e.g. generalised sepsis
• CPC Class Codes: G01N 33/6803 General methods of protein analysis not limited to specific proteins or families of proteins

Abstract

The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual'"'"'s profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual'"'"'s biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual'"'"'s biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

Claims

1-91. -91. (canceled)

92. A method of predicting sepsis in a human SIRS patient comprising

a) determining the abundances of at least three biomarker proteins in a blood or plasma sample from a human SIRS patient, wherein the three biomarker proteins are selected from apolipoprotein A1 (apoA1), apolipoprotein CIII (apoCIII), β

-2 microglobulin (β

2M), C reactive protein (CRP), macrophage chemoattractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), macrophage inflammatory protein-1β

(MIP-1β

), serum amyloid P (SAP) and tissue inhibitor of metalloproteinase-1 (TIMP-1); and

b) comparing the abundances of the biomarker proteins in the sample to features corresponding to abundances of the at least three biomarker proteins present in a first reference profile taken from a SIRS-positive human reference population that did not progress to sepsis,

wherein sepsis is predicted in the SIRS patient when it is determined that the abundances of the at least three biomarker proteins are (i) greater than the abundances in the first reference profile where the biomarker proteins are β

2M, CRP, MCP-1, MMP-9, MIP-1β

, SAP or TIMP-1, or (ii) less than the abundances in the first reference profile where the biomarker proteins are apoA1 or apoCIII.

93. The method of claim 92, wherein the abundances of at least four biomarker proteins selected from apoA1, apoCIII, β

2M, CRP, MCP-1, MMP-9, MIP-1β

, SAP and TIMP-1 are determined in step (a) and compared in step (b).

94. The method of claim 92, wherein the abundances of at least five biomarker proteins selected from apoA1, apoCIII, β

2M, CRP, MCP-1, MMP-9, MIP-1β

, SAP and TIMP-1 are determined in step (a) and compared in step (b).

95. The method of claim 92 further comprising comparing the abundances of the biomarker proteins in the sample to features corresponding to abundances of the at least three biomarker proteins present in a second reference profile taken from a SIRS-positive human reference population that progressed to sepsis.

96. The method of claim 95, wherein the second reference profile is obtained from blood or plasma samples taken 0-36 hours prior to sepsis in the SIRS-positive human reference population that progressed to sepsis.

97. The method of claim 95, wherein the second reference profile is obtained from blood or plasma samples taken 36-60 hours prior to sepsis in the SIRS-positive human reference population that progressed to sepsis.

98. The method of claim 95, wherein the second reference profile is obtained from blood or plasma samples taken 60-84 hours prior to sepsis in the SIRS-positive human reference population that progressed to sepsis.

99. The method of claim 92, further comprising comparing the abundances of the biomarker proteins in the sample to features corresponding to abundances of the at least three biomarker proteins present in a third reference profile taken from a non-SIRS, non-septic healthy human reference population.

100. The method of claim 92, further comprising determining the abundances in the sample from the SIRS patient of one or more biomarker proteins selected from Tables 15-23 of the specification other than apoA1, apoCIII, β

2M, CRP, MCP-1, MMP-9, MIP-1β

, SAP and TIMP-1 and comparing the abundances of the one or more biomarker proteins in the sample to features corresponding to abundances of the one or more biomarker proteins present in the first reference profile taken from the SIRS-positive human reference population that did not progress to sepsis.

101. The method of claim 92, wherein the comparison comprises applying a decision rule.

102. The method of claim 101, wherein applying the decision rule comprises using a data analysis algorithm.

103. The method of claim 102, wherein the data analysis algorithm comprises the use of a classification tree.

104. The method of claim 102, wherein the data analysis algorithm is nonparametric.

105. The method of claim 104, wherein the data analysis algorithm detects differences in a distribution of feature values.

106. The method of claim 105, wherein the nonparametric algorithm comprises using a Wilcoxon Signed Rank Test.

107. The method of claim 102, wherein the data analysis algorithm comprises using a multiple additive regression tree.

108. The method of claim 102, wherein the data analysis algorithm is a logistic regression.

109. The method of claim 101, wherein the decision rule determines the status of sepsis in the individual with an accuracy of at least 60%.

110. The method of claim 109, wherein the decision rule determines the status of sepsis in the individual with an accuracy of at least 70%.

111. The method of claim 110, wherein the decision rule determines the status of sepsis in the individual with an accuracy of at least 80%.

112. The method of claim 109, wherein the decision rule has been subjected to ten-fold cross-validation.

113. The method of claim 92, wherein the SIRS-positive human reference population that did not progress to sepsis comprises at least two individuals.

114. The method of claim 113, wherein the SIRS-positive human reference population that did not progress to sepsis comprises at least 20 individuals.

115. The method of claim 92, wherein determining the abundances of the at least three biomarker proteins comprises contacting the at least three biomarkers proteins with at least three antibodies or a functional fragments thereof that specifically bind each of the at least biomarker proteins.

116. The method of claim 115, wherein said antibody or a functional fragment thereof is detectably labeled.

117. The method of claim 92, wherein determining the abundances of the at least three biomarker proteins comprises contacting the at least three biomarkers proteins with immobilized antibodies.

118. The method of claim 92, wherein the blood or plasma sample from the human SIRS patient is fractionated prior to determining the abundances of the at least three biomarker proteins.

119. The method of claim 92, wherein at least one separation method is used to determine the abundances of the at least three biomarker proteins in the blood or plasma sample.

120. The method of claim 119, wherein at least two separation methods are used to determine the abundances of the at least three biomarker proteins in the blood or plasma sample.

121. The method of claim 119, wherein said at least one separation method comprises mass spectrometry.

122. The method of claim 121, wherein said mass spectrometry is selecting from the group consisting of electrospray ionization mass spectrometry (ESI-MS), ESI-MS/MS, ESI-MS/(MS), matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), desorption/ionization on silicon (DIOS), secondary ion mass spectrometry (SIMS), quadrupole time-of-flight (Q-TOF), atmospheric pressure chemical ionization mass spectrometry (APCI-MS), APCI-MS/MS, APCI-(MS)ⁿ, atmospheric pressure photoionization mass spectrometry (APPI-MS), APPI-MS/MS, and APPI-(MS)ⁿ, quadrupole mass spectrometry, fourier transform mass spectrometry (FTMS), and ion trap mass spectrometry, where n is an integer greater than zero.

123. The method of claim 122, wherein the at least one separation method comprises SELDI-TOF-MS.

124. The method of claim 119, wherein the at least one separation method is selected from the group consisting of chemical extraction partitioning, ion exchange chromatography, reverse phase liquid chromatography, isoelectric focusing, one-dimensional polyacrylamide gel electrophoresis (PAGE), two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), thin-layer chromatography, gas chromatography, liquid chromatography, and any combination thereof.

125. A method of predicting sepsis in a human SIRS patient comprising

a) determining the abundances of at least three proteins in a first blood or plasma sample from a human SIRS patient, wherein the three proteins are selected from apoA1, apoCIII, β

2M, CRP, MCP-1, MMP-9, MIP-1β

, SAP and TIMP-1;

b) determining the abundances of the at least three proteins in a second blood or plasma sample from a human SIRS patient; and

c) comparing the abundances of the proteins in the second blood or plasma sample to features corresponding to abundances of the at least three proteins present in the first blood or plasma sample,

wherein sepsis is predicted in the SIRS patient when it is determined that the abundances of the at least three protein in the second blood or plasma sample are (i) greater than the abundances in the first blood or plasma sample where the proteins are β

2M, CRP, MCP-1, MMP-9, MIP-1β

, SAP or TIMP-1, or (ii) less than the abundances in the first blood or plasma sample where the proteins are apoA1 or apoCIII.

126. The method of claim 125, wherein the first blood or plasma sample and second blood or plasma sample are taken about 24 hours apart from the SIRS patient.

127. A method of determining that a SIRS patient is not likely to develop sepsis comprising

a) detecting abundances of at least three biomarker proteins in a blood or plasma sample from a human SIRS patient, wherein the three biomarker proteins are selected from apolipoprotein A1 (apoA1), apolipoprotein CIII (apoCIII), β

-2 microglobulin (β

2M), C reactive protein (CRP), macrophage chemoattractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), macrophage inflammatory protein-1β

(MIP-1β

), serum amyloid P (SAP) and tissue inhibitor of metalloproteinase-1 (TIMP-1); and

b) comparing the abundances of the biomarker proteins in the sample to features corresponding to abundances of the at least three biomarker proteins present in a first reference profile taken from a SIRS-positive human reference population that progressed to sepsis,

wherein it is determined that the SIRS patient is not likely to develop sepsis within 48 hours from when the blood or plasma sample was taken from the SIRS patient when the abundances of the at least three biomarker proteins in the sample differ from those in the first reference profile.

128. The method of claim 127 further comprising comparing the abundances of the biomarker proteins in the sample to features corresponding to abundances of the at least three biomarker proteins present in a second reference profile taken from a SIRS-positive human reference population that did not progress to sepsis.